 PITTSBURGH, Aug. 09, 2021 GLOBE NEWSWIRE -- Krystal Biotech Inc., Krystal NASDAQ: KRYS, the leader in redosable gene therapies for rare diseases, today reported financial results and key operational progress updates for the second quarter ending June 30, 2021. 